var data={"title":"Bipolar disorder in adults: Treating major depression with second-generation antipsychotics","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Bipolar disorder in adults: Treating major depression with second-generation antipsychotics</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/contributors\" class=\"contributor contributor_credentials\">William V Bobo, MD, MPH</a></dd><dd><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/contributors\" class=\"contributor contributor_credentials\">Richard C Shelton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/contributors\" class=\"contributor contributor_credentials\">Paul Keck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/contributors\" class=\"contributor contributor_credentials\">David Solomon, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 10, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H36032236\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although manic and hypomanic episodes are diagnostic hallmarks for bipolar disorder, depressive episodes predominate the lifetime course of illness and result in greater disability and risk of suicide [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Bipolar major depression is often treated with antidepressants, but their use is controversial because these drugs may not be effective and may cause switches from depression to mania as well as rapid cycling. Other drugs that are widely used for bipolar depression include second-generation antipsychotics [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/3\" class=\"abstract_t\">3</a>]. </p><p>This topic reviews the efficacy, safety, and tolerability of second-generation antipsychotics for bipolar major depression. Choosing a medication regimen for bipolar major depression, mania, hypomania, and the maintenance treatment of bipolar disorder are discussed separately, as is the efficacy and safety of antidepressants for bipolar major depression:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=bipolar-disorder-in-adults-pharmacotherapy-for-acute-depression\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Pharmacotherapy for acute depression&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-pharmacotherapy-for-acute-mania-and-hypomania\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Choosing pharmacotherapy for acute mania and hypomania&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-maintenance-treatment\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Choosing maintenance treatment&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=bipolar-disorder-in-adults-treating-major-depression-with-antidepressants\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Treating major depression with antidepressants&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1837115\"><span class=\"h1\">DEFINITION OF BIPOLAR DISORDER</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bipolar disorder is a mood disorder that is characterized by episodes of mania (<a href=\"image.htm?imageKey=PSYCH%2F91106\" class=\"graphic graphic_table graphicRef91106 \">table 1</a>), hypomania (<a href=\"image.htm?imageKey=PSYCH%2F91107\" class=\"graphic graphic_table graphicRef91107 \">table 2</a>), and major depression (<a href=\"image.htm?imageKey=PSYCH%2F91398\" class=\"graphic graphic_table graphicRef91398 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/4\" class=\"abstract_t\">4</a>]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-clinical-features\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Clinical features&quot;</a> and <a href=\"topic.htm?path=bipolar-disorder-in-adults-assessment-and-diagnosis#H4503550\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Assessment and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H36032348\"><span class=\"h1\">EFFICACY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For outpatients with bipolar major depression and no comorbid substance use disorders, randomized trials have established the efficacy of <a href=\"topic.htm?path=lurasidone-drug-information\" class=\"drug drug_general\">lurasidone</a>, <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a>, and <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/5-10\" class=\"abstract_t\">5-10</a>], and suggest that <a href=\"topic.htm?path=cariprazine-drug-information\" class=\"drug drug_general\">cariprazine</a> is also effective [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/11\" class=\"abstract_t\">11</a>]. By contrast, multiple trials have found no benefit in using <a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-drug-information\" class=\"drug drug_general\">aripiprazole</a> and <a href=\"topic.htm?path=ziprasidone-drug-information\" class=\"drug drug_general\">ziprasidone</a> [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/12,13\" class=\"abstract_t\">12,13</a>]. Other second-generation antipsychotics that may possibly be helpful include <a href=\"topic.htm?path=asenapine-drug-information\" class=\"drug drug_general\">asenapine</a>, <a href=\"topic.htm?path=clozapine-drug-information\" class=\"drug drug_general\">clozapine</a>, <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a>, but their benefit has yet to be established. (See <a href=\"#H5519998\" class=\"local\">'Other second-generation antipsychotics'</a> below.)</p><p>In addition, second-generation antipsychotics are often used as monotherapy or in combination with other drugs for mania, as well maintenance treatment of patients with bipolar disorder. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-pharmacotherapy-for-acute-mania-and-hypomania\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Choosing pharmacotherapy for acute mania and hypomania&quot;</a> and <a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-maintenance-treatment\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Choosing maintenance treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7300681\"><span class=\"h2\">Quetiapine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">Quetiapine</a> monotherapy is efficacious for bipolar major depression, based upon multiple meta-analyses of randomized trials [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/5,14\" class=\"abstract_t\">5,14</a>]. As an example, one meta-analysis of five trials (3057 patients treated for eight weeks) compared quetiapine with placebo (limited use of <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a> and hypnotics was allowed for the first three to four weeks); the primary findings were as follows [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/7\" class=\"abstract_t\">7</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Remission occurred in more patients who received <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> than placebo (61 versus 42 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduction of anxiety symptoms was greater with <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Remission was comparable for <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> 300 mg per day and 600 mg per day</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Improvement in quality of life (satisfaction) was superior with <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> than placebo</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Remission rates were lower for patients with more severe depressive episodes</p><p/><p>However, meta-analyses of the same five trials found that discontinuation of treatment because of side effects occurred in more patients who received <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> than placebo (24 versus 6 percent), and was greater for quetiapine 600 mg per day than 300 mg per day [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/5,7\" class=\"abstract_t\">5,7</a>]. Adverse effects that occurred more often with quetiapine than placebo included:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sedation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Weight gain</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dry mouth</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Headache</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dizziness</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nausea</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Constipation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Extrapyramidal symptoms</p><p/><p>Additional information about <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> side effects (<a href=\"image.htm?imageKey=PSYCH%2F82533\" class=\"graphic graphic_table graphicRef82533 \">table 4</a> and <a href=\"image.htm?imageKey=EM%2F80747\" class=\"graphic graphic_table graphicRef80747 \">table 5</a>) is discussed separately. </p><p class=\"headingAnchor\" id=\"H7300807\"><span class=\"h3\">Bipolar II major depression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Randomized trials for bipolar disorder often exclude patients with bipolar II disorder or combine them with bipolar I patients in the analyses. However, several trials of <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> monotherapy included bipolar II patients with major depression and found that the drug was effective for this subgroup: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two randomized trials, each lasting eight weeks, compared <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> (300 or 600 mg at bedtime) with placebo in patients with bipolar major depression [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/15\" class=\"abstract_t\">15</a>]. A pooled analysis of the subgroup of 321 patients with bipolar II depression found that remission was greater with quetiapine 300 or 600 <span class=\"nowrap\">mg/day,</span> compared with placebo (39 and 38 versus 20 percent). This was consistent with the finding that both doses of quetiapine were superior in the total sample of bipolar patients [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/16\" class=\"abstract_t\">16</a>]. Among patients with bipolar II depression, discontinuation of treatment due to adverse effects of quetiapine 300 <span class=\"nowrap\">mg/day</span> and 600 <span class=\"nowrap\">mg/day</span> and placebo were 16, 23, and 2 percent; common side effects of quetiapine included dry mouth, sedation, fatigue, and dizziness.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An eight week randomized trial compared <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> (300 or 600 mg at bedtime) with placebo in patients with bipolar major depression [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/17\" class=\"abstract_t\">17</a>]. In the subgroup of 208 patients with bipolar II disorder, symptoms improved more with both doses of quetiapine than placebo; this was consistent with the finding that quetiapine was superior in patients with bipolar I disorder. </p><p/><p class=\"headingAnchor\" id=\"H86357398\"><span class=\"h3\">Compared with other drugs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although head to head randomized trials seem to suggest that <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> monotherapy is superior to <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> monotherapy or <a href=\"topic.htm?path=paroxetine-drug-information\" class=\"drug drug_general\">paroxetine</a> monotherapy for bipolar major depression, the comparative benefit of quetiapine is not clear due to methodologic problems:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One eight week trial assigned patients to <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> 300 mg per day (N = 255), quetiapine 600 mg per day (N = 263), or <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> (target serum concentration 0.6 to 1.2 <span class=\"nowrap\">mEq/L</span> [0.6 to 1.2 <span class=\"nowrap\">mmol/L];</span> N = 136) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/18\" class=\"abstract_t\">18</a>]. Although symptoms improved more with either dose of quetiapine than with lithium, the study was underpowered for lithium [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/19\" class=\"abstract_t\">19</a>]. In addition, the mean serum concentration of lithium was 0.61 <span class=\"nowrap\">mEq/L</span> (0.61 <span class=\"nowrap\">mmol/L),</span> and more than a third of the patients treated with lithium had a median serum concentration &lt;0.6 <span class=\"nowrap\">mEq/L</span> (&lt;0.6 <span class=\"nowrap\">mmol/L)</span>. &#160;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One eight week trial assigned patients to <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> 300 mg per day (N = 229), quetiapine 600 mg per day (N = 232), or <a href=\"topic.htm?path=paroxetine-drug-information\" class=\"drug drug_general\">paroxetine</a> 20 mg per day (N = 118) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/17\" class=\"abstract_t\">17</a>]. Although symptoms improved more with either dose of quetiapine than with paroxetine, the study was underpowered for paroxetine. In addition, the paroxetine dose was at the low end of the dose range that is usually used to treat major depression (<a href=\"image.htm?imageKey=PC%2F53818\" class=\"graphic graphic_table graphicRef53818 \">table 6</a>).</p><p/><p class=\"headingAnchor\" id=\"H173197880\"><span class=\"h2\">Olanzapine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with bipolar major depression, randomized trials have demonstrated the efficacy of <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> monotherapy [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/20\" class=\"abstract_t\">20</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One six week trial compared <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> (5 to 20 mg per day) with placebo in 514 patients; use of concomitant medication was not reported. Remission occurred in more patients who received olanzapine than placebo (38 versus 29 percent), and discontinuation of treatment due to adverse effects was comparable (9 and 8 percent) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One eight week trial compared <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> (5 to 20 mg per day) with placebo in 706 patients; benzodiazepines and anticholinergic drugs were allowed as well. Remission occurred in more patients who received olanzapine than placebo (33 versus 25 percent) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/6\" class=\"abstract_t\">6</a>]. However, discontinuation of treatment due to adverse effects occurred in more patients who received olanzapine than placebo (9 versus 5 percent). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another eight week trial compared <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> (mean dose 14 mg per day) with placebo in 68 patients; hypnotic and anticholinergic drugs were allowed as well [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/21\" class=\"abstract_t\">21</a>]. Remission occurred in more patients who received olanzapine than placebo (35 versus 12 percent). </p><p/><p>In addition, subgroup analyses have found that in patients with mixed features [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/22\" class=\"abstract_t\">22</a>] and patients with anxiety symptoms [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/6\" class=\"abstract_t\">6</a>], <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> is more effective than placebo.</p><p><a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">Olanzapine</a> can cause serious weight gain and may also cause diabetes mellitus [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/23-25\" class=\"abstract_t\">23-25</a>]. In the randomized trials that compared olanzapine with placebo in patients with bipolar major depression, the following adverse effects occurred more often with olanzapine [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/6,8,21\" class=\"abstract_t\">6,8,21</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sedation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Weight gain</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased appetite</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dry mouth</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Weakness</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Headache</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypercholesterolemia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypertriglyceridemia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hyperglycemia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alanine aminotransferase abnormally high</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aspartate aminotransferase abnormally high</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gamma glutamyl transpeptidase abnormally high</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hyperprolactinemia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neutropenia</p><p/><p>Additional information about <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> side effects (<a href=\"image.htm?imageKey=PSYCH%2F82533\" class=\"graphic graphic_table graphicRef82533 \">table 4</a> and <a href=\"image.htm?imageKey=EM%2F80747\" class=\"graphic graphic_table graphicRef80747 \">table 5</a>) is discussed separately. </p><p class=\"headingAnchor\" id=\"H173197887\"><span class=\"h3\">Olanzapine plus fluoxetine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The combination of <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> and <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">fluoxetine</a> can help patients with bipolar major depression. In one eight-week trial that compared olanzapine plus fluoxetine (6 and 25, 6 and 50, or 12 and 50 mg per day), olanzapine monotherapy (5 to 20 mg per day), and placebo in 833 patients, remission occurred in more patients who received olanzapine plus fluoxetine than olanzapine alone or placebo (49 versus 33 and 25 percent) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/6\" class=\"abstract_t\">6</a>]. However, side effects of the combination included weight gain, increased appetite, dry mouth, weakness, and diarrhea. Additional information about the efficacy of olanzapine plus fluoxetine is discussed separately, as is the risk of switching from depression to mania. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-treating-major-depression-with-antidepressants\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Treating major depression with antidepressants&quot;</a>.) </p><p>The side effects of <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> monotherapy (<a href=\"image.htm?imageKey=PSYCH%2F82533\" class=\"graphic graphic_table graphicRef82533 \">table 4</a> and <a href=\"image.htm?imageKey=EM%2F80747\" class=\"graphic graphic_table graphicRef80747 \">table 5</a>) and <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">fluoxetine</a> monotherapy (<a href=\"image.htm?imageKey=PC%2F62488\" class=\"graphic graphic_table graphicRef62488 \">table 7</a>) are discussed elsewhere. (See <a href=\"#H173197880\" class=\"local\">'Olanzapine'</a> above and <a href=\"topic.htm?path=selective-serotonin-reuptake-inhibitors-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H357179\"><span class=\"h2\">Lurasidone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For bipolar I major depression, randomized trials indicate that <a href=\"topic.htm?path=lurasidone-drug-information\" class=\"drug drug_general\">lurasidone</a> is efficacious either as monotherapy or as add-on treatment with <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> or <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a>:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A six week trial compared <a href=\"topic.htm?path=lurasidone-drug-information\" class=\"drug drug_general\">lurasidone</a> 20 to 60 mg per day, lurasidone 80 to 120 mg per day, and placebo in 505 patients, and found that improvement of symptoms and functional impairment was greater with each lurasidone group than placebo (the benefit of the two lurasidone dose ranges was similar) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/9\" class=\"abstract_t\">9</a>]. In addition, discontinuation of treatment due to adverse effects was similar for the three treatment groups (approximately 6 to 7 percent of patients within each group). Lurasidone was also efficacious in the subgroup of patients with bipolar I major depression with mixed features [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/26\" class=\"abstract_t\">26</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A six week trial enrolled 348 patients who had not adequately responded to at least one month of treatment with either <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> monotherapy or <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a> monotherapy, and randomly assigned them to adjunctive treatment with <a href=\"topic.htm?path=lurasidone-drug-information\" class=\"drug drug_general\">lurasidone</a> (20 to 120 mg per day) or placebo [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/10\" class=\"abstract_t\">10</a>]. Remission occurred in more patients who received add-on lurasidone than placebo (50 versus 35 percent). Discontinuation of treatment due to adverse effects was comparable for lurasidone and placebo (6 and 8 percent of patients). &#160;</p><p/><p>In the two trials, the most frequently reported side effects of <a href=\"topic.htm?path=lurasidone-drug-information\" class=\"drug drug_general\">lurasidone</a> were [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/9,10\" class=\"abstract_t\">9,10</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Akathisia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Headache</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Insomnia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nausea</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sedation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tremor</p><p/><p>A prospective follow-up study enrolled patients who received <a href=\"topic.htm?path=lurasidone-drug-information\" class=\"drug drug_general\">lurasidone</a> or placebo as monotherapy or adjunctive therapy for bipolar major depression in randomized trials and completed the trials [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/27\" class=\"abstract_t\">27</a>]. The follow-up study lasted for six months, during which all patients (n = 817) received open label treatment with lurasidone (20 to 120 <span class=\"nowrap\">mg/day)</span>. On average, patients showed further improvement of depressive symptoms; however, discontinuation of treatment due to adverse events occurred in 8 percent. </p><p>Based upon our clinical experience, administering <a href=\"topic.htm?path=lurasidone-drug-information\" class=\"drug drug_general\">lurasidone</a> with food (eg, &gt;350 calories) may limit gastrointestinal side effects. Additional information about lurasidone side effects are shown in the table (<a href=\"image.htm?imageKey=PSYCH%2F82533\" class=\"graphic graphic_table graphicRef82533 \">table 4</a>). </p><p class=\"headingAnchor\" id=\"H1580868972\"><span class=\"h2\">Cariprazine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cariprazine-drug-information\" class=\"drug drug_general\">Cariprazine</a> appears to be efficacious for bipolar major depression. One randomized trial compared cariprazine (0.75, 1.5, or 3 <span class=\"nowrap\">mg/day)</span> with placebo for six weeks in patients with bipolar major depression (n = 571) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/11\" class=\"abstract_t\">11</a>]. Across multiple outcomes, cariprazine 1.5 <span class=\"nowrap\">mg/day</span> was superior to placebo; as an example, remission occurred in more patients who received cariprazine 1.5 <span class=\"nowrap\">mg/day</span> than placebo (30 versus 16 percent). Cariprazine 3 <span class=\"nowrap\">mg/day</span> was more efficacious than placebo on some outcomes, but not others. Cariprazine 0.75 <span class=\"nowrap\">mg/day</span> provided little advantage over placebo. Discontinuation of treatment due to adverse events was comparable for the four groups. Akathisia was the most common adverse effect of cariprazine, and occurred in a dose-dependent fashion.</p><p class=\"headingAnchor\" id=\"H5519998\"><span class=\"h2\">Other second-generation antipsychotics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Low quality evidence (eg, indirect outcome, lack of placebo or other control, or small sample), as well as unpublished studies, suggests that monotherapy with other second-generation antipsychotics may possibly be useful for treating bipolar major depression:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=asenapine-drug-information\" class=\"drug drug_general\">Asenapine</a> &ndash; A pooled analysis of two randomized trials, each lasting three weeks, compared asenapine (5 or 10 mg twice per day) with placebo in a subgroup of 173 patients with major depression concurrent with mania [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/28\" class=\"abstract_t\">28</a>]. Remission occurred in more patients treated with asenapine than placebo (45 versus 24 percent); this was consistent with the finding that asenapine was superior in the total sample of patients with mania. However, among patients with concurrent depression and mania, sedation, dizziness, extrapyramidal symptoms, and weight gain occurred more often with asenapine than placebo.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=clozapine-drug-information\" class=\"drug drug_general\">Clozapine</a> &ndash; A retrospective observational study of 326 patients treated with adjunctive clozapine (mean dose 307 mg per day) for up to two years found that the number of hospitalizations and number of days in the hospital were lower during clozapine treatment than the same period of time immediately prior to use of clozapine [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/29\" class=\"abstract_t\">29</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">Risperidone</a> &ndash; One trial enrolled 30 patients with an incomplete response to <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, or <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a> and randomly assigned the patients to receive adjunctive risperidone, <a href=\"topic.htm?path=paroxetine-drug-information\" class=\"drug drug_general\">paroxetine</a>, or risperidone plus paroxetine [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/30\" class=\"abstract_t\">30</a>]. All three groups improved. &#160; </p><p/><p>The side effects (<a href=\"image.htm?imageKey=PSYCH%2F82533\" class=\"graphic graphic_table graphicRef82533 \">table 4</a> and <a href=\"image.htm?imageKey=EM%2F80747\" class=\"graphic graphic_table graphicRef80747 \">table 5</a>) of these drugs are discussed separately. (See <a href=\"topic.htm?path=second-generation-antipsychotic-medications-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Second-generation antipsychotic medications: Pharmacology, administration, and side effects&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H36032278\"><span class=\"h2\">Drugs with little to no benefit</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with bipolar major depression, multiple randomized trials indicate that there is little to no benefit in using <a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-drug-information\" class=\"drug drug_general\">aripiprazole</a> or <a href=\"topic.htm?path=ziprasidone-drug-information\" class=\"drug drug_general\">ziprasidone</a>: &#160;</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-drug-information\" class=\"drug drug_general\">Aripiprazole</a> &ndash; Two eight-week trials compared aripiprazole (5 to 30 mg per day) with placebo in a total of 749 patients; a pooled analysis found that the benefits of aripiprazole and placebo were comparable [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/12\" class=\"abstract_t\">12</a>] </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ziprasidone-drug-information\" class=\"drug drug_general\">Ziprasidone</a> &ndash; Two six-week trials compared ziprasidone (20 to 80 mg twice daily) with placebo in a total of 856 patients; in each trial, ziprasidone demonstrated no advantage [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/13,31\" class=\"abstract_t\">13,31</a>]</p><p/><p class=\"headingAnchor\" id=\"H36032292\"><span class=\"h2\">Rapid cycling bipolar disorder</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The efficacy of second-generation antipsychotics to treat bipolar major depression in rapid cycling patients is discussed separately. (See <a href=\"topic.htm?path=rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression#H92694034\" class=\"medical medical_review\">&quot;Rapid cycling bipolar disorder in adults: Treatment of major depression&quot;, section on 'Treatment'</a>.)</p><p class=\"headingAnchor\" id=\"H2229622\"><span class=\"h2\">Geriatric bipolar disorder</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The efficacy of second-generation antipsychotics to treat bipolar major depression in geriatric patients is discussed separately. (See <a href=\"topic.htm?path=geriatric-bipolar-disorder-acute-treatment#H361190789\" class=\"medical medical_review\">&quot;Geriatric bipolar disorder: Acute treatment&quot;, section on 'First-line treatment'</a>.)</p><p class=\"headingAnchor\" id=\"H36032356\"><span class=\"h1\">SAFETY AND TOLERABILITY</span></p><p class=\"headingAnchor\" id=\"H259519902\"><span class=\"h2\">Side effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Side effects associated with second-generation antipsychotics include weight gain, hyperglycemia, type 2 diabetes mellitus, hyperlipidemia, sedation, hyperprolactinemia, neuroleptic malignant syndrome, orthostatic hypotension, sudden death, and an increased risk of mortality when used to treat psychiatric symptoms associated with dementia in elderly patients (<a href=\"image.htm?imageKey=PSYCH%2F82533\" class=\"graphic graphic_table graphicRef82533 \">table 4</a> and <a href=\"image.htm?imageKey=EM%2F80747\" class=\"graphic graphic_table graphicRef80747 \">table 5</a>). Second-generation antipsychotics can also cause extrapyramidal symptoms and tardive dyskinesia, but at rates lower than first-generation drugs. These side effects and their management are described separately. (See <a href=\"topic.htm?path=second-generation-antipsychotic-medications-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Second-generation antipsychotic medications: Pharmacology, administration, and side effects&quot;</a> and <a href=\"topic.htm?path=pharmacotherapy-for-schizophrenia-side-effect-management\" class=\"medical medical_review\">&quot;Pharmacotherapy for schizophrenia: Side effect management&quot;</a> and <a href=\"topic.htm?path=causes-of-hyperprolactinemia\" class=\"medical medical_review\">&quot;Causes of hyperprolactinemia&quot;</a> and <a href=\"topic.htm?path=neuroleptic-malignant-syndrome\" class=\"medical medical_review\">&quot;Neuroleptic malignant syndrome&quot;</a> and <a href=\"topic.htm?path=acquired-long-qt-syndrome-definitions-causes-and-pathophysiology\" class=\"medical medical_review\">&quot;Acquired long QT syndrome: Definitions, causes, and pathophysiology&quot;</a> and <a href=\"topic.htm?path=tardive-dyskinesia-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Tardive dyskinesia: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=tardive-dyskinesia-prevention-and-treatment\" class=\"medical medical_review\">&quot;Tardive dyskinesia: Prevention and treatment&quot;</a>.)</p><p>General principles regarding the safety and tolerability of second-generation antipsychotics in bipolar major depression include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with bipolar depression may be more sensitive to side effects than patients with mania [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/32,33\" class=\"abstract_t\">32,33</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The risk of extrapyramidal side effects and tardive dyskinesia is thought to be higher in bipolar disorder than schizophrenia [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/34,35\" class=\"abstract_t\">34,35</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment emergent mania does not occur in patients who are treated with <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> or <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/6-8,36\" class=\"abstract_t\">6-8,36</a>]</p><p/><p>In addition, adverse effects can lead to poor adherence [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/37\" class=\"abstract_t\">37</a>].</p><p class=\"headingAnchor\" id=\"H259517724\"><span class=\"h3\">Metabolic effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The risk of metabolic side effects (eg, weight gain, hyperlipidemia, and hyperglycemia) is increased with some second-generation antipsychotics [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/38\" class=\"abstract_t\">38</a>]; this is important given the increased risk of metabolic syndrome [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/39\" class=\"abstract_t\">39</a>] as well as cardiovascular morbidity and mortality in patients with bipolar disorder relative to the general population [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/40-42\" class=\"abstract_t\">40-42</a>]. Although most studies of second-generation antipsychotics and metabolic effects involve schizophrenia [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/38\" class=\"abstract_t\">38</a>], comparable effects have been found in bipolar disorder [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/5,36,43,44\" class=\"abstract_t\">5,36,43,44</a>]. Among second-generation antipsychotics, the greatest risk for metabolic effects is with <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> and <a href=\"topic.htm?path=clozapine-drug-information\" class=\"drug drug_general\">clozapine</a>, followed by <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> and <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a> (<a href=\"image.htm?imageKey=PSYCH%2F82533\" class=\"graphic graphic_table graphicRef82533 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/45\" class=\"abstract_t\">45</a>]. The risk of clinically significant weight gain for olanzapine monotherapy and olanzapine plus <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">fluoxetine</a> appears to be comparable [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/6,46\" class=\"abstract_t\">6,46</a>]. <a href=\"topic.htm?path=lurasidone-drug-information\" class=\"drug drug_general\">Lurasidone</a> does not cause short-term weight gain, whereas <a href=\"topic.htm?path=asenapine-drug-information\" class=\"drug drug_general\">asenapine</a> does [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/47\" class=\"abstract_t\">47</a>].</p><p>Prior to initiating treatment with second-generation antipsychotics, we ask patients about their personal and family history of obesity, diabetes, dyslipidemia, hypertension, cardiovascular disease, and family history of sudden cardiac death [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/45\" class=\"abstract_t\">45</a>].</p><p class=\"headingAnchor\" id=\"H259518705\"><span class=\"h3\">Sedation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Among patients with bipolar major depression, <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> and <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> often cause somnolence that leads to discontinuation of treatment [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/33\" class=\"abstract_t\">33</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In an eight week randomized trial that compared <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> with placebo in 706 patients, discontinuation of treatment due to adverse effects occurred in more patients treated with olanzapine than placebo (9 versus 5 percent) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/6\" class=\"abstract_t\">6</a>]. Among patients who discontinued olanzapine because of side effects, the most frequent cause was sedation. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A meta-analysis of five randomized trials (2477 patients treated for eight weeks) that compared <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> with placebo found that discontinuation of treatment due to somnolence was nearly five times more likely in patients who received quetiapine [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/7\" class=\"abstract_t\">7</a>]</p><p/><p class=\"headingAnchor\" id=\"H173197509\"><span class=\"h2\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bipolar patients who are treated with second-generation antipsychotics should be assessed for [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/45,48\" class=\"abstract_t\">45,48</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Metabolic side effects at baseline and periodically thereafter (<a href=\"image.htm?imageKey=PSYCH%2F74435\" class=\"graphic graphic_table graphicRef74435 \">table 8</a>) &#160; </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Extrapyramidal symptoms at baseline and subsequently at every visit. Patients should also be monitored for tardive dyskinesia at baseline, quarterly in the first year, and annually thereafter, using the Abnormal Involuntary Movement Scale (AIMS) (<a href=\"image.htm?imageKey=PSYCH%2F51103\" class=\"graphic graphic_form graphicRef51103 \">form 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Orthostatic hypotension at baseline and periodically thereafter </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prolactin elevation at baseline and periodically thereafter </p><p/><p>In addition, patients may need to be monitored for QT prolongation. Additional information about assessing patients for metabolic side effects, extrapyramidal symptoms, orthostasis, hyperprolactinemia, and QT prolongation is discussed further in the context of schizophrenia. (See <a href=\"topic.htm?path=pharmacotherapy-for-schizophrenia-side-effect-management\" class=\"medical medical_review\">&quot;Pharmacotherapy for schizophrenia: Side effect management&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H36032399\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Medications regimens for bipolar patients are selected according to the phase of illness. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-pharmacotherapy-for-acute-depression\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Pharmacotherapy for acute depression&quot;</a> and <a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-pharmacotherapy-for-acute-mania-and-hypomania\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Choosing pharmacotherapy for acute mania and hypomania&quot;</a> and <a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-maintenance-treatment\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Choosing maintenance treatment&quot;</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">Quetiapine</a> monotherapy is efficacious for short term treatment of bipolar major depression; however the drug can cause sedation, weight gain, dry mouth, headache, dizziness, nausea, constipation, and extrapyramidal symptoms. (See <a href=\"#H7300681\" class=\"local\">'Quetiapine'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">Olanzapine</a> monotherapy is efficacious for short term treatment of bipolar major depression; however, the drug can cause serious weight gain and may also cause diabetes mellitus. Other adverse effects include sedation, increased appetite, dry mouth, weakness, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, abnormally high liver functions tests, hyperprolactinemia, and neutropenia. (See <a href=\"#H173197880\" class=\"local\">'Olanzapine'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">Olanzapine</a> plus <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">fluoxetine</a> is efficacious for short term treatment of bipolar major depression; however, the combination can cause weight gain, increased appetite, dry mouth, weakness, and diarrhea. (See <a href=\"#H173197887\" class=\"local\">'Olanzapine plus fluoxetine'</a> above.) &#160;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=lurasidone-drug-information\" class=\"drug drug_general\">Lurasidone</a> is efficacious either as monotherapy or as add-on treatment with <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> or <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a>. However, lurasidone can cause akathisia, headache, insomnia, nausea, sedation, and tremor. (See <a href=\"#H357179\" class=\"local\">'Lurasidone'</a> above.) &#160;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cariprazine-drug-information\" class=\"drug drug_general\">Cariprazine</a> also appears to be efficacious for treating bipolar major depression. Other second-generation antipsychotics that may possibly be useful include <a href=\"topic.htm?path=asenapine-drug-information\" class=\"drug drug_general\">asenapine</a>, <a href=\"topic.htm?path=clozapine-drug-information\" class=\"drug drug_general\">clozapine</a>, and <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a>. (See <a href=\"#H1580868972\" class=\"local\">'Cariprazine'</a> above and <a href=\"#H5519998\" class=\"local\">'Other second-generation antipsychotics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with bipolar major depression, there is little to no benefit in using <a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-drug-information\" class=\"drug drug_general\">aripiprazole</a> or <a href=\"topic.htm?path=ziprasidone-drug-information\" class=\"drug drug_general\">ziprasidone</a>. (See <a href=\"#H36032278\" class=\"local\">'Drugs with little to no benefit'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Side effects associated with second-generation antipsychotics include weight gain, hyperglycemia, type 2 diabetes mellitus, hyperlipidemia, sedation, hyperprolactinemia, extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, orthostatic hypotension, sudden death, and an increased risk of mortality when used to treat psychiatric symptoms associated with dementia in elderly patients (<a href=\"image.htm?imageKey=PSYCH%2F82533\" class=\"graphic graphic_table graphicRef82533 \">table 4</a> and <a href=\"image.htm?imageKey=EM%2F80747\" class=\"graphic graphic_table graphicRef80747 \">table 5</a>). (See <a href=\"#H259519902\" class=\"local\">'Side effects'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among second-generation antipsychotics, the greatest risk for metabolic effects (eg, weight gain, hyperlipidemia, and hyperglycemia) is with <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> and <a href=\"topic.htm?path=clozapine-drug-information\" class=\"drug drug_general\">clozapine</a>, followed by <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> and <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a> (<a href=\"image.htm?imageKey=PSYCH%2F82533\" class=\"graphic graphic_table graphicRef82533 \">table 4</a>). The risk of clinically significant weight gain appears to be comparable for olanzapine monotherapy and olanzapine plus <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">fluoxetine</a>. <a href=\"topic.htm?path=lurasidone-drug-information\" class=\"drug drug_general\">Lurasidone</a> does not cause short-term weight gain, whereas <a href=\"topic.htm?path=asenapine-drug-information\" class=\"drug drug_general\">asenapine</a> does. (See <a href=\"#H259517724\" class=\"local\">'Metabolic effects'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among patients with bipolar major depression, <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> and <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> often cause somnolence that leads to discontinuation of treatment. (See <a href=\"#H259518705\" class=\"local\">'Sedation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bipolar patients who are treated with second-generation antipsychotics should be monitored for metabolic side effects (<a href=\"image.htm?imageKey=PSYCH%2F74435\" class=\"graphic graphic_table graphicRef74435 \">table 8</a>), extrapyramidal symptoms, tardive dyskinesia (<a href=\"image.htm?imageKey=PSYCH%2F51103\" class=\"graphic graphic_form graphicRef51103 \">form 1</a>), orthostatic hypotension, and prolactin elevation. In addition, patients may need to be monitored for QT prolongation. (See <a href=\"#H173197509\" class=\"local\">'Monitoring'</a> above.) </p><p/><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/1\" class=\"nounderline abstract_t\">Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59:530.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/2\" class=\"nounderline abstract_t\">Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60:261.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/3\" class=\"nounderline abstract_t\">Greil W, H&auml;berle A, Haueis P, et al. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord 2012; 136:534.</a></li><li class=\"breakAll\">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/5\" class=\"nounderline abstract_t\">De Fruyt J, Deschepper E, Audenaert K, et al. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol 2012; 26:603.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/6\" class=\"nounderline abstract_t\">Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/7\" class=\"nounderline abstract_t\">Chiesa A, Chierzi F, De Ronchi D, Serretti A. Quetiapine for bipolar depression: a systematic review and meta-analysis. Int Clin Psychopharmacol 2012; 27:76.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/8\" class=\"nounderline abstract_t\">Tohen M, McDonnell DP, Case M, et al. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry 2012; 201:376.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/9\" class=\"nounderline abstract_t\">Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014; 171:160.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/10\" class=\"nounderline abstract_t\">Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014; 171:169.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/11\" class=\"nounderline abstract_t\">Durgam S, Earley W, Lipschitz A, et al. An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression. Am J Psychiatry 2016; 173:271.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/12\" class=\"nounderline abstract_t\">Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008; 28:13.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/13\" class=\"nounderline abstract_t\">Lombardo I, Sachs G, Kolluri S, et al. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol 2012; 32:470.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/14\" class=\"nounderline abstract_t\">Vieta E, Locklear J, G&uuml;nther O, et al. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J Clin Psychopharmacol 2010; 30:579.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/15\" class=\"nounderline abstract_t\">Suppes T, Hirschfeld RM, Vieta E, et al. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 2008; 9:198.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/16\" class=\"nounderline abstract_t\">Weisler RH, Calabrese JR, Thase ME, et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008; 69:769.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/17\" class=\"nounderline abstract_t\">McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71:163.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/18\" class=\"nounderline abstract_t\">Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71:150.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/19\" class=\"nounderline abstract_t\">Grunze HC. Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression. Evid Based Ment Health 2010; 13:88.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/20\" class=\"nounderline abstract_t\">Tohen M, Katagiri H, Fujikoshi S, Kanba S. Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies. J Affect Disord 2013; 149:196.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/21\" class=\"nounderline abstract_t\">Wang M, Tong JH, Huang DS, et al. Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized, double-blind, placebo controlled study. Psychopharmacology (Berl) 2014; 231:2811.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/22\" class=\"nounderline abstract_t\">Tohen M, Kanba S, McIntyre RS, et al. Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. J Affect Disord 2014; 164:57.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/23\" class=\"nounderline abstract_t\">Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161:1709.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/24\" class=\"nounderline abstract_t\">Fernandez-Egea E, Miller B, Garcia-Rizo C, et al. Metabolic effects of olanzapine in patients with newly diagnosed psychosis. J Clin Psychopharmacol 2011; 31:154.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/25\" class=\"nounderline abstract_t\">Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry 2010; 23:574.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/26\" class=\"nounderline abstract_t\">McIntyre RS, Cucchiaro J, Pikalov A, et al. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry 2015; 76:398.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/27\" class=\"nounderline abstract_t\">Ketter TA, Sarma K, Silva R, et al. LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY. Depress Anxiety 2016; 33:424.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/28\" class=\"nounderline abstract_t\">Azorin JM, Sapin C, Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. J Affect Disord 2013; 145:62.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/29\" class=\"nounderline abstract_t\">Nielsen J, Kane JM, Correll CU. Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord 2012; 14:863.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/30\" class=\"nounderline abstract_t\">Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 2004; 65:1715.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/31\" class=\"nounderline abstract_t\">Sachs GS, Ice KS, Chappell PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72:1413.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/32\" class=\"nounderline abstract_t\">Wang Z, Kemp DE, Chan PK, et al. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. Int J Neuropsychopharmacol 2011; 14:131.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/33\" class=\"nounderline abstract_t\">Gao K, Ganocy SJ, Gajwani P, et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 2008; 69:302.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/34\" class=\"nounderline abstract_t\">Keck PE Jr, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000; 61 Suppl 4:33.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/35\" class=\"nounderline abstract_t\">Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008; 28:203.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/36\" class=\"nounderline abstract_t\">Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry 2007; 7:40.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/37\" class=\"nounderline abstract_t\">Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/38\" class=\"nounderline abstract_t\">Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl 1:1.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/39\" class=\"nounderline abstract_t\">Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013; 170:265.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/40\" class=\"nounderline abstract_t\">Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry 2011; 23:40.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/41\" class=\"nounderline abstract_t\">Goldstein BI, Fagiolini A, Houck P, Kupfer DJ. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord 2009; 11:657.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/42\" class=\"nounderline abstract_t\">Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58:844.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/43\" class=\"nounderline abstract_t\">Torrent C, Amann B, S&aacute;nchez-Moreno J, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand 2008; 118:4.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/44\" class=\"nounderline abstract_t\">Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2011; 72:1063.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/45\" class=\"nounderline abstract_t\">American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/46\" class=\"nounderline abstract_t\">Tamayo JM, Sutton VK, Mattei MA, et al. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J Clin Psychopharmacol 2009; 29:358.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/47\" class=\"nounderline abstract_t\">De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 2012; 26:733.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-adults-treating-major-depression-with-second-generation-antipsychotics/abstract/48\" class=\"nounderline abstract_t\">Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 16693 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H36032399\"><span>SUMMARY</span></a></li><li><a href=\"#H36032236\" id=\"outline-link-H36032236\">INTRODUCTION</a></li><li><a href=\"#H1837115\" id=\"outline-link-H1837115\">DEFINITION OF BIPOLAR DISORDER</a></li><li><a href=\"#H36032348\" id=\"outline-link-H36032348\">EFFICACY</a><ul><li><a href=\"#H7300681\" id=\"outline-link-H7300681\">Quetiapine</a><ul><li><a href=\"#H7300807\" id=\"outline-link-H7300807\">- Bipolar II major depression</a></li><li><a href=\"#H86357398\" id=\"outline-link-H86357398\">- Compared with other drugs</a></li></ul></li><li><a href=\"#H173197880\" id=\"outline-link-H173197880\">Olanzapine</a><ul><li><a href=\"#H173197887\" id=\"outline-link-H173197887\">- Olanzapine plus fluoxetine</a></li></ul></li><li><a href=\"#H357179\" id=\"outline-link-H357179\">Lurasidone</a></li><li><a href=\"#H1580868972\" id=\"outline-link-H1580868972\">Cariprazine</a></li><li><a href=\"#H5519998\" id=\"outline-link-H5519998\">Other second-generation antipsychotics</a></li><li><a href=\"#H36032278\" id=\"outline-link-H36032278\">Drugs with little to no benefit</a></li><li><a href=\"#H36032292\" id=\"outline-link-H36032292\">Rapid cycling bipolar disorder</a></li><li><a href=\"#H2229622\" id=\"outline-link-H2229622\">Geriatric bipolar disorder</a></li></ul></li><li><a href=\"#H36032356\" id=\"outline-link-H36032356\">SAFETY AND TOLERABILITY</a><ul><li><a href=\"#H259519902\" id=\"outline-link-H259519902\">Side effects</a><ul><li><a href=\"#H259517724\" id=\"outline-link-H259517724\">- Metabolic effects</a></li><li><a href=\"#H259518705\" id=\"outline-link-H259518705\">- Sedation</a></li></ul></li><li><a href=\"#H173197509\" id=\"outline-link-H173197509\">Monitoring</a></li></ul></li><li><a href=\"#H36032399\" id=\"outline-link-H36032399\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PSYCH/16693|Form\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FORMS\">FORMS</a></div><ul><li><a href=\"image.htm?imageKey=PSYCH/51103\" class=\"graphic graphic_form\">- Abnormal involuntary movement scale</a></li></ul></li><li><div id=\"PSYCH/16693|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PSYCH/91106\" class=\"graphic graphic_table\">- DSM-5 diagnostic criteria for manic episode</a></li><li><a href=\"image.htm?imageKey=PSYCH/91107\" class=\"graphic graphic_table\">- DSM-5 diagnostic criteria for hypomanic episode</a></li><li><a href=\"image.htm?imageKey=PSYCH/91398\" class=\"graphic graphic_table\">- DSM-5 diagnostic criteria for bipolar major depression</a></li><li><a href=\"image.htm?imageKey=PSYCH/82533\" class=\"graphic graphic_table\">- Adverse effects of antipsychotic meds</a></li><li><a href=\"image.htm?imageKey=EM/80747\" class=\"graphic graphic_table\">- Adverse effects of atypical antipsychotic medications</a></li><li><a href=\"image.htm?imageKey=PC/53818\" class=\"graphic graphic_table\">- Pharmacology antidepressants</a></li><li><a href=\"image.htm?imageKey=PC/62488\" class=\"graphic graphic_table\">- Side effects antidepressants</a></li><li><a href=\"image.htm?imageKey=PSYCH/74435\" class=\"graphic graphic_table\">- Monitoring for metabolic side effects of antipsychotic drugs</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-long-qt-syndrome-definitions-causes-and-pathophysiology\" class=\"medical medical_review\">Acquired long QT syndrome: Definitions, causes, and pathophysiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-assessment-and-diagnosis\" class=\"medical medical_review\">Bipolar disorder in adults: Assessment and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-maintenance-treatment\" class=\"medical medical_review\">Bipolar disorder in adults: Choosing maintenance treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-pharmacotherapy-for-acute-mania-and-hypomania\" class=\"medical medical_review\">Bipolar disorder in adults: Choosing pharmacotherapy for acute mania and hypomania</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-clinical-features\" class=\"medical medical_review\">Bipolar disorder in adults: Clinical features</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-pharmacotherapy-for-acute-depression\" class=\"medical medical_review\">Bipolar disorder in adults: Pharmacotherapy for acute depression</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-treating-major-depression-with-antidepressants\" class=\"medical medical_review\">Bipolar disorder in adults: Treating major depression with antidepressants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-hyperprolactinemia\" class=\"medical medical_review\">Causes of hyperprolactinemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=geriatric-bipolar-disorder-acute-treatment\" class=\"medical medical_review\">Geriatric bipolar disorder: Acute treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neuroleptic-malignant-syndrome\" class=\"medical medical_review\">Neuroleptic malignant syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacotherapy-for-schizophrenia-side-effect-management\" class=\"medical medical_review\">Pharmacotherapy for schizophrenia: Side effect management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression\" class=\"medical medical_review\">Rapid cycling bipolar disorder in adults: Treatment of major depression</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=second-generation-antipsychotic-medications-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">Second-generation antipsychotic medications: Pharmacology, administration, and side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=selective-serotonin-reuptake-inhibitors-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tardive-dyskinesia-clinical-features-and-diagnosis\" class=\"medical medical_review\">Tardive dyskinesia: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tardive-dyskinesia-prevention-and-treatment\" class=\"medical medical_review\">Tardive dyskinesia: Prevention and treatment</a></li></ul></div></div>","javascript":null}